Search

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

114.31 4.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

107.52

Max

116.99

Belangrijke statistieken

By Trading Economics

Inkomsten

64M

-41M

Verkoop

21M

92M

EPS

-0.61

Winstmarge

-44.904

Werknemers

414

EBITDA

7.8M

-36M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+36.21% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

7.9B

Vorige openingsprijs

110.11

Vorige sluitingsprijs

114.31

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 nov 2026, 21:01 UTC

Rhythm Pharmaceuticals, Inc. is trading significantly higher today, with unusually high market volume and currently positioned near the upper end of its one-month range.

12 nov 2026, 21:13 UTC

Rhythm Pharmaceuticals, Inc. is trading modestly higher in after-market hours, reflecting a cumulative return of nearly 1% following Thursday's close.

11 nov 2026, 22:01 UTC

Rhythm Pharmaceuticals, Inc. is trading lower in after-market hours, having declined below Wednesday's close before recovering slightly from an initial low.

10 nov 2026, 20:46 UTC

News

Rhythm Pharmaceuticals shares are higher as the company reports a significant rise in IMCIVREE sales and speculation of a $124 takeover bid from AstraZeneca.

9 nov 2026, 21:07 UTC

Rhythm Pharmaceuticals, Inc. shares advanced, maintaining a higher trajectory since Friday's close, with overall performance robust and trading above its 20-day moving average.

6 nov 2026, 23:46 UTC

Rhythm Pharmaceuticals, Inc. is experiencing a slight decline in after-market trading, moving lower from a peak shortly after the market closed.

5 nov 2026, 23:31 UTC

Rhythm Pharmaceuticals, Inc. shares are moving lower in after-market trading, reflecting a decline since Thursday's close amid broader market downturns.

4 nov 2026, 23:02 UTC

Social Media
Event
News

AstraZeneca made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals, proposing $124 per share, according to The Wall Street Journal.

3 nov 2026, 21:02 UTC

News

Rhythm Pharmaceuticals reports a Q3 net loss of $42.4 million, or $0.61 per share, exceeding revenue estimates but falling short of analyst expectations.

2 nov 2026, 21:04 UTC

Rhythm Pharmaceuticals, Inc. shares are trading higher today, with notable volume and positioning above their 20-day moving average, despite an earlier pullback.

30 okt 2026, 20:08 UTC

Correlated Moves

Rhythm Pharmaceuticals shares are declining amid a broader downturn in the biotechnology sector, influenced by significant drops in the SPDR S&P Biotech ETF (XBI).

28 okt 2026, 20:07 UTC

Macro Event

Rhythm Pharmaceuticals shares are declining amid broader market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 okt 2026, 20:07 UTC

Correlated Moves

Rhythm Pharmaceuticals, Inc. shares are advancing, supported by a broader rally in the biotechnology sector and gains in the SPDR S&P Biotech ETF (XBI).

22 okt 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares are advancing amid a significant upward movement in the Biotechnology sub-sector, gaining ground since Wednesday's close.

21 okt 2026, 19:46 UTC

News

Shares of Rhythm Pharmaceuticals Inc fell sharply, trading significantly below its 20-day moving average ahead of its Q3 2026 financial results announcement on November 3, 2026.

20 okt 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is trading higher in after-market hours, continuing a trend of three consecutive sessions that have also closed higher.

19 okt 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading on Monday.

15 okt 2026, 20:07 UTC

News

Rhythm Pharmaceuticals receives an Overweight rating from JPMorgan, with the price target adjusted to $145.00, reflecting a continued positive outlook.

14 okt 2026, 19:56 UTC

News
Event

Rhythm Pharmaceuticals Inc launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial data.

13 okt 2026, 22:11 UTC

Correlated Moves

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading, correlating with slight gains in the Direxion Daily S&P Biotech Bull 3X ETF.

12 okt 2026, 19:46 UTC

Rhythm Pharmaceuticals Inc shares fell, fluctuating within a routine range and remaining significantly below its 20-day moving average.

9 okt 2026, 20:07 UTC

Social Media

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8 okt 2026, 20:01 UTC

News

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7 okt 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6 okt 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5 okt 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2 okt 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1 okt 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29 sep 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24 sep 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

36.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 149.643 USD  36.21%

Hoogste 206 USD

Laagste 120 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

14

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat